Description
RetaCag (Retatrutide + Cagrilintide) Acetate Blend
Contents (per vial):
- 5 mg Retatrutide Acetate
- 1 mg Cagrilintide Acetate
Structural Characteristics:
RetaCag combines two advanced, long-acting peptide analogs for multi-receptor metabolic research:
- Retatrutide – a lipidated synthetic triagonist activating GLP-1, GIP, and glucagon receptors, incorporating a C20 fatty diacid at Lys20 via an AEEA linker for enhanced albumin binding and prolonged activity.
- Cagrilintide – a 37-amino acid amylin receptor agonist analog conjugated with a C20 fatty diacid for extended half-life and sustained receptor activation.
This combination offers complementary mechanisms to influence metabolic, satiety, and energy regulation pathways.
Mechanism of Action (Research Context):
RetaCag is studied for potential synergistic effects in:
- Appetite regulation and satiety signaling models
- Glycemic control and insulin sensitivity studies
- Body weight reduction and energy expenditure research
- Hepatic fat metabolism and obesity-related investigations
Synthesis and Quality Control:
- Manufactured via solid-phase peptide synthesis (SPPS)
- Each peptide purified to ≥98% by HPLC
- Identity verified via Mass Spectrometry (MS)
Product Details:
- Form: Lyophilized acetate salt blend
- Appearance: White to off-white powder
- Supplied in: 3mL sterile vial
Solubility & Reconstitution:
Soluble in sterile water, dilute acetic acid, or aqueous buffers at pH 5–7.
- Gently swirl to dissolve; avoid vigorous shaking
- Protect from high pH and oxidation to maintain peptide integrity
Storage & Handling:
- Store lyophilized powder at –20°C, away from light and moisture
- After reconstitution, refrigerate at 2–8°C for up to 30 days
- For long-term storage, aliquot and freeze at –20°C
- Avoid repeated freeze-thaw cycles
Disclaimer:
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic applications.
